VFA
DNTH icon

Valeo Financial Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Valeo Financial Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-31
Closed -$7K – 1579
2019
Q2 		$7K Hold
31
– – ﹤0.01% 1111
2019
Q1 		$8K Hold
31
– – ﹤0.01% 1019
2018
Q4 		$3K Hold
31
– – ﹤0.01% 1196
2018
Q3 		$4K Hold
31
– – ﹤0.01% 1259
2018
Q2 		$6K Buy
+31
New +$7K ﹤0.01% 1078

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Valeo Financial Advisors's DNTH Position: Q3 2019 in Review

Valeo Financial Advisors sold out of Dianthus Therapeutics (DNTH) in Q3 2019, closing a stake of 31 shares — an estimated $7K sold.

Valeo Financial Advisors first reported a position in DNTH in Q2 2018 and held it in 5 quarters. The position peaked at $8K in Q1 2019. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

  • Valeo Financial Advisors reported no remaining Dianthus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 31 Dianthus Therapeutics shares in Q3 2019, an estimated $7K.
  • Valeo Financial Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 5 quarters.
  • Valeo Financial Advisors's Dianthus Therapeutics position peaked at $8K in Q1 2019.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Valeo Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.